Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus FOLFIRI versus best supportive care in third- or fourth-line metastatic colorectal cancer
MOH_2018-04-18_002325Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Masitinib + FOLFIRI with Best Supportive Care (2 arms). Planned start Mar 2018; status: not yet recruiting.
02
Drugs
masitinib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2018-04-18_002325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-18_002325.